Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials
Wirksamkeit von Safran versus selektiven Serotonin-Wiederaufnahmehemmern (SSRIs) in der Behandlung von Depression und Angst: Metaanalyse randomisierter kontrollierter Studien
Nutrition Reviews · 01.03.2025 · 83 (3) · e751-e761
DOI: 10.1093/nutrit/nuae076 ↗Auf einen Blick
Die Metaanalyse fand bei Depression und Angst keinen signifikanten Unterschied zwischen Safran und SSRIs. Unter Safran traten weniger unerwünschte Ereignisse auf.
Fragestellung
Wie wirksam und verträglich ist Safran im Vergleich zu SSRIs bei Erwachsenen mit Depression oder Angst?
Methode
Systematische Übersichtsarbeit und Metaanalyse von RCTs; Suche in PubMed, Embase, Scopus, Web of Science und Cochrane-Datenbank bis 31. April 2023.
Ergebnisse
8 Studien zu Depression: kein signifikanter Unterschied in der Symptomreduktion (SMD 0,10; 95 %-KI –0,09 bis 0,29). 4 Studien zu Angst: ebenfalls kein signifikanter Unterschied (SMD 0,04; 95 %-KI –0,22 bis 0,29). Unerwünschte Ereignisse seltener mit Safran (Risikodifferenz –0,06; 95 %-KI –0,09 bis –0,04; I2: 0%).
Einschränkungen
Weitere Forschung mit größeren Stichproben und in diversen Populationen erforderlich.
Schlussfolgerung der Autor:innen
Safran könnte eine potenzielle Alternative zu SSRIs sein, um depressive und Angstsymptome mit weniger unerwünschten Ereignissen zu reduzieren.
Kernaussagen
- Depression: kein signifikanter Unterschied zu SSRIs
- Angst: kein signifikanter Unterschied zu SSRIs
- Weniger unerwünschte Ereignisse unter Safran
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Metaanalyse in der Zeitschrift Nutrition Reviews, online erschienen am 24.06.2024. Verfasst von Arman Shafiee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, School of Medicine, Alborz University of Medical Science, Karaj, Iran. Hauptthemen laut MEDLINE: Anti-Anxiety Agents, Antidepressive Agents, Anxiety, Crocus. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
Context
Saffron, a natural remedy with potential antidepressant and anxiolytic properties, has gained attention as a potential therapeutic option.
Objective
This systematic review and meta-analysis aimed to evaluate the comparative effectiveness of saffron versus selective serotonin reuptake inhibitors (SSRIs) in treating depression and anxiety. Data Source Electronic databases, including PubMed, Embase, Scopus, Web of Science, and the Cochrane database, were searched from inception to April 31, 2023. Data Extraction Randomized controlled trials (RCTs) comparing saffron intervention with SSRIs in adults with depression or anxiety were included. Data Analysis Random-effects meta-analysis using standardized mean differences (SMDs) and risk ratio (RRs) with their 95% CIs calculated continuous and binary outcomes, respectively. Meta-analysis of 8 studies assessing depression outcomes revealed a nonsignificant difference between saffron and SSRIs in reducing depressive symptoms (SMD = 0.10l 95% CI: –0.09 to 0.29). Four studies reporting anxiety outcomes showed a nonsignificant difference between saffron and SSRIs in reducing anxiety symptoms (SMD = 0.04; 95% CI: –0.22 to 0.29). With regard to safety, participants receiving saffron had fewer adverse events than the SSRI group (risk difference: –0.06; 95% CI: –0.09, –0.04; I2: 0%).
Conclusion
Saffron could be a potential SSRI alternative to reduce depressive and anxiety symptoms with fewer adverse events. Further research with larger sample sizes and in diverse populations is warranted to validate these findings and explore potential moderators of treatment response. Systematic Review Registration PROSPERO registration no. CRD42023443236.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, School of Medicine, Alborz University of Medical Science, Karaj, Iran.
- Department of Psychiatry and Mental Health, Alborz University of Medical Sciences, Karaj, Iran.
- Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
- Department of Community Medicine, Alborz University of Medical Sciences, Karaj, 3149779453, Iran.
ORCID-Profile: Arman Shafiee, Mahmood Bakhtiyari
Zitieren
APA
Shafiee, A., Jafarabady, K., Seighali, N., Mohammadi, I., Rajai Firouz Abadi, S., Abhari, F. S., & Bakhtiyari, M. (2025). Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials. Nutrition Reviews, 83(3), e751-e761. https://doi.org/10.1093/nutrit/nuae076
Vancouver
Shafiee A, Jafarabady K, Seighali N, Mohammadi I, Rajai Firouz Abadi S, Abhari FS, et al. Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials. Nutrition Reviews. 2025;83(3):e751-e761. doi:10.1093/nutrit/nuae076
BibTeX
@article{Shafiee2025,
author = {Shafiee, Arman and Jafarabady, Kyana and Seighali, Niloofar and Mohammadi, Ida and Rajai Firouz Abadi, Shahryar and Abhari, Faeze Soltani and Bakhtiyari, Mahmood},
title = {Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials},
journal = {Nutrition Reviews},
year = {2025},
volume = {83},
number = {3},
pages = {e751--e761},
doi = {10.1093/nutrit/nuae076}
}
EUVIMED